Currently, there are 192.74M common shares owned by the public and among those 189.83M shares have been available to trade.
The company’s stock has a 5-day price change of -3.17% and -18.28% over the past three months. BLUE shares are trading -33.09% year to date (YTD), with the 12-month market performance down to -74.91% lower. It has a 12-month low price of $0.88 and touched a high of $5.53 over the same period. BLUE has an average intraday trading volume of 8.29 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.50%, -26.29%, and -62.22% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bluebird bio Inc (NASDAQ: BLUE) shares accounts for 62.01% of the company’s 192.74M shares outstanding.
It has a market capitalization of $177.98M and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.20% over the week and 8.22% over the month.
Analysts forecast that Bluebird bio Inc (BLUE) will achieve an EPS of -$0.64 for the current quarter, -$0.44 for the next quarter and -$1.61 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.98 while analysts give the company a high EPS estimate of -$0.45. Comparatively, EPS for the current quarter was $0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 10.88%, and 45.28% over the next financial year.
Morgan Stanley coverage for the Bluebird bio Inc (BLUE) stock in a research note released on December 08, 2023 offered a Equal-Weight rating with a price target of $7. Cantor Fitzgerald was of a view on October 17, 2023 that the stock is Neutral, while HSBC Securities gave the stock Buy rating on September 06, 2023, issuing a price target of $4.21. BofA Securities on their part issued Buy rating on July 19, 2023.
